MX2017009695A - Objetivo terapeutico y biomarcador en enfermedad inflamatoria intestinal (ibd). - Google Patents
Objetivo terapeutico y biomarcador en enfermedad inflamatoria intestinal (ibd).Info
- Publication number
- MX2017009695A MX2017009695A MX2017009695A MX2017009695A MX2017009695A MX 2017009695 A MX2017009695 A MX 2017009695A MX 2017009695 A MX2017009695 A MX 2017009695A MX 2017009695 A MX2017009695 A MX 2017009695A MX 2017009695 A MX2017009695 A MX 2017009695A
- Authority
- MX
- Mexico
- Prior art keywords
- individual
- osm
- methods
- osmr
- inflammatory bowel
- Prior art date
Links
- 239000000090 biomarker Substances 0.000 title 1
- 102000004140 Oncostatin M Human genes 0.000 abstract 4
- 108090000630 Oncostatin M Proteins 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 230000000968 intestinal effect Effects 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5412—IL-6
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1501480.6A GB201501480D0 (en) | 2015-01-29 | 2015-01-29 | Biomarker |
| GB201501511A GB201501511D0 (en) | 2015-01-29 | 2015-01-29 | Biomarker |
| GBGB1521446.3A GB201521446D0 (en) | 2015-12-04 | 2015-12-04 | Biomarker |
| PCT/GB2016/050185 WO2016120625A1 (en) | 2015-01-29 | 2016-01-28 | Biomarker |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017009695A true MX2017009695A (es) | 2018-04-10 |
Family
ID=55299667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017009695A MX2017009695A (es) | 2015-01-29 | 2016-01-28 | Objetivo terapeutico y biomarcador en enfermedad inflamatoria intestinal (ibd). |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10822406B2 (enExample) |
| EP (2) | EP3250599B1 (enExample) |
| JP (1) | JP6999417B2 (enExample) |
| KR (1) | KR20170132143A (enExample) |
| CN (1) | CN107530431B (enExample) |
| AU (1) | AU2016210996B2 (enExample) |
| MX (1) | MX2017009695A (enExample) |
| WO (1) | WO2016120625A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201614627D0 (en) * | 2016-08-30 | 2016-10-12 | Glaxosmithkline Ip Dev Ltd | Antigen binding proteins |
| EP3554362A4 (en) * | 2016-12-14 | 2020-08-12 | Warren, Tracy | SYSTEM AND METHODS FOR DEVELOPING AND USING A MICROBIOME-BASED ACTION COMPONENT FOR PATIENT HEALTH |
| US11978543B2 (en) | 2016-12-14 | 2024-05-07 | Astarte Medical Partners Inc. | System and methods for developing and using a microbiome-based action component |
| JP2021522241A (ja) * | 2018-04-25 | 2021-08-30 | キニクサ ファーマシューティカルズ, リミテッド | 抗osmrβ抗体の送達による皮膚疾患又は障害の治療 |
| US11779643B2 (en) * | 2019-08-28 | 2023-10-10 | Children's Hospital Medical Center | Methods and compositions for the treatment of an inflammatory bowel disease |
| JP7620324B2 (ja) * | 2019-08-29 | 2025-01-23 | 国立大学法人東北大学 | 炎症性腸疾患の診断方法、診断プローブ及び診断キット |
| CN113699187B (zh) * | 2020-05-20 | 2023-08-08 | 中国科学院微生物研究所 | 一种肠易激综合征小鼠模型及其应用 |
| KR20230092978A (ko) | 2020-10-19 | 2023-06-26 | 조에티스 서비시즈 엘엘씨 | 개 및 고양이 온코스타틴 m 수용체 베타에 대한 항체 및 이의 용도 |
| IL285031A (en) * | 2021-07-21 | 2023-02-01 | Yeda Res & Dev | Diagnosis of inflammatory bowel diseases |
| CN116377048B (zh) * | 2022-04-22 | 2024-05-07 | 广州市妇女儿童医疗中心 | S100a8/a9复合体在诊治先天性巨结肠中的应用 |
| WO2025049876A1 (en) * | 2023-09-01 | 2025-03-06 | Genentech, Inc. | Methods for treating inflammatory bowel disease |
| WO2025153079A1 (en) * | 2024-01-19 | 2025-07-24 | Biomap (Suzhou) Intelligent Technology Limited | Method of treatment |
| CN119955922A (zh) * | 2025-01-15 | 2025-05-09 | 浙江大学 | 生物标志物在制备炎症性肠病筛查或亚型检测产品的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6693130B2 (en) | 1999-02-18 | 2004-02-17 | Regents Of The University Of California | Inhibitors of epoxide hydrolases for the treatment of hypertension |
| US6531506B1 (en) | 1996-08-13 | 2003-03-11 | Regents Of The University Of California | Inhibitors of epoxide hydrolases for the treatment of hypertension |
| US5958442A (en) | 1997-10-24 | 1999-09-28 | Bristol-Myers Squibb Company | Oncostatin M for treating inflammation |
| GB9806530D0 (en) * | 1998-03-26 | 1998-05-27 | Glaxo Group Ltd | Inflammatory mediator |
| US8563525B2 (en) | 2004-01-12 | 2013-10-22 | Natrogen Therapeutics International, Inc. | Methods of treating an inflammatory-related disease |
| EP1671642A1 (en) | 2004-12-15 | 2006-06-21 | Universite D'angers | Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof. |
| US7572896B2 (en) | 2005-02-03 | 2009-08-11 | Raven Biotechnologies, Inc. | Antibodies to oncostatin M receptor |
| WO2007143231A2 (en) * | 2006-01-10 | 2007-12-13 | Zymogenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists |
| EP1904050B1 (en) | 2005-06-06 | 2012-11-14 | The Regents of The University of California | Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy |
| US20080293582A1 (en) | 2006-08-30 | 2008-11-27 | Xilin Li | Markers and Methods for Assessing and Treating Ulcerative Colitis and Related Disorders Using a 43 Gene Panel |
| WO2008028044A2 (en) | 2006-08-30 | 2008-03-06 | Centocor, Inc. | Markers and methods for assessing and treating ulcerative colitis and related disorders using 66 gene panel |
| WO2010044952A2 (en) | 2008-08-25 | 2010-04-22 | Centocor Ortho Biotech Inc. | Biomarkers for anti-tnf treatment in ulcerative colitis and related disorders |
| CN103209731A (zh) | 2010-09-30 | 2013-07-17 | 赢创有限公司 | 药物输送刀片及用于将药物储仓输送到目标部位的方法 |
| PH12013500703A1 (en) | 2010-10-13 | 2013-05-20 | Janssen Biotech Inc | Human oncostatin m antibodies and methods of use |
| PL2643352T3 (pl) * | 2010-11-23 | 2018-10-31 | Glaxo Group Limited | Białka wiążące antygen wiążące onkostatynę M (OSM) |
| WO2013168829A1 (en) | 2012-05-11 | 2013-11-14 | Wakayama Medical University | Anti oncostatin m receptor beta antibody |
| BR112015028338A2 (pt) | 2013-05-17 | 2017-07-25 | Genentech Inc | métodos de diagnóstico ou de auxílio no diagnóstico e de tratamento da doença inflamatória intestinal |
| TR201815608T4 (tr) | 2013-05-30 | 2018-11-21 | Kiniksa Pharmaceuticals Ltd | Onkastatin m reseptörü antijeni bağlayıcı proteinler. |
-
2016
- 2016-01-28 AU AU2016210996A patent/AU2016210996B2/en active Active
- 2016-01-28 MX MX2017009695A patent/MX2017009695A/es unknown
- 2016-01-28 KR KR1020177024112A patent/KR20170132143A/ko not_active Withdrawn
- 2016-01-28 EP EP16702773.9A patent/EP3250599B1/en active Active
- 2016-01-28 WO PCT/GB2016/050185 patent/WO2016120625A1/en not_active Ceased
- 2016-01-28 CN CN201680015517.5A patent/CN107530431B/zh active Active
- 2016-01-28 EP EP21168214.1A patent/EP3974450A3/en active Pending
- 2016-01-28 JP JP2017540056A patent/JP6999417B2/ja active Active
- 2016-01-28 US US15/547,154 patent/US10822406B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN107530431B (zh) | 2022-01-07 |
| JP2018506528A (ja) | 2018-03-08 |
| EP3250599B1 (en) | 2021-04-14 |
| US20180022800A1 (en) | 2018-01-25 |
| AU2016210996A1 (en) | 2017-08-17 |
| WO2016120625A1 (en) | 2016-08-04 |
| US10822406B2 (en) | 2020-11-03 |
| CN107530431A (zh) | 2018-01-02 |
| KR20170132143A (ko) | 2017-12-01 |
| JP6999417B2 (ja) | 2022-02-04 |
| AU2016210996B2 (en) | 2021-08-12 |
| EP3974450A2 (en) | 2022-03-30 |
| EP3250599A1 (en) | 2017-12-06 |
| EP3974450A3 (en) | 2022-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017009695A (es) | Objetivo terapeutico y biomarcador en enfermedad inflamatoria intestinal (ibd). | |
| CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
| EP3542332A4 (en) | BLOCK CHAIN SYSTEM FOR SUPPORTING PUBLIC AND PRIVATE TRANSACTIONS IN ACCOUNT MODELS | |
| BR112017009159A2 (pt) | métodos e biomarcadores para predizer a eficácia e avaliação de um tratamento com agonista de ox40 | |
| MX367046B (es) | Marcadores especificos de via para diagnosticar sindrome del intestino irritable. | |
| MX392671B (es) | Antagonistas de unión a pd-l1 y usos de los mismos para el tratamiento de cáncer | |
| PH12016500331A1 (en) | Survival benefit in patients with solid tumors with elevated c-reactive protein levels | |
| FR3010624B1 (fr) | Procede et systeme de cartographie, procede et systeme d'evaluation de l'efficacite d'une stimulation medullaire | |
| MX2016002423A (es) | Composiciones y metodos de diagnostico para el tratamiento de glioblastoma. | |
| MX2015009392A (es) | Biomarcadores de terapia de combinacion anti-tnf y anti-il17 para enfermedades inflamatorias. | |
| EP3875605C0 (en) | METHOD FOR DIAGNOSIS AND PROGNOSIS OF CHRONIC HEART FAILURE | |
| GB2535034A (en) | Methods and systems for microbiome characterization, monitoring and treatment | |
| MX2024001909A (es) | Metodos y composiciones para el diagnostico y el tratamiento de trastornos en pacientes con elevados niveles de cxcl9 y otros biomarcadores. | |
| BR112016016101A2 (pt) | Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos | |
| MX2016008516A (es) | Metodos terapeuticos y composiciones. | |
| MX2018010536A (es) | Metodos y composiciones para deteccion y diagnostico de enfermedades renales y enfermedades periodontales. | |
| BR112017025995A2 (pt) | inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal | |
| WO2016030334A3 (en) | Methods, agents and compositions for treatment of inflammatory conditions | |
| MX2020006660A (es) | Biomarcadores de tolerancia inmunitaria inducida por metotrexato. | |
| BR112015032526A2 (pt) | composições anticaspa e métodos de uso das mesmas | |
| MX384423B (es) | Biomarcadores para la respuesta a inhibidores del mejorador del homólogo 2 de zeste (ezh2). | |
| BR112017001971A2 (pt) | ?métodos e composições para diagnosticar e tratar distúrbios inflamatórios intestinais? | |
| MX2018000528A (es) | Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo. | |
| WO2015169973A3 (de) | Markersequenzen zur diagnose und stratifizierung von systemische sklerose patienten | |
| EA201891478A1 (ru) | Способы и композиции для оценки риска возникновения рака |